DOI QR코드

DOI QR Code

Incidence of Cisplatin-Induced Nephrotoxicity and Associated Factors among Cancer Patients in Indonesia

  • Prasaja, Yenny (Faculty of Pharmacy, Universitas Indonesia) ;
  • Sutandyo, Noorwati (Division of Hematology-Medical Oncology, Dharmais National Cancer Hospital) ;
  • Andrajati, Retnosari (Faculty of Pharmacy, Universitas Indonesia)
  • Published : 2015.03.04

Abstract

Background: Cisplatin is still used as a first-line medication for solid tumors. Nephrotoxicity is a serious side effect that can decrease renal function and restrict applicable doses. This research aimed to obtain the profile of cisplatin-induced nephrotoxicity and its associated factors in adult cancer patients at Dharmais National Cancer Hospital (DNCH). Materials and Methods: The design was cross-sectional with data obtained from patient medical records. We retrospectively reviewed adult cancer patients treated with cisplatin ${\geq}60mg/m^2$ for at least four consecutive chemotherapy cycles from August 2011 to November 2013. The nephrotoxicity criterion was renal function decline characterized by creatinine clearance <60 ml/min using the Cockroft-Gault (CG) equation. Results: Eighty-eight subjects received at least four chemotherapy cycles of cisplatin. The prevalence of cisplatin nephrotoxicity was 34.1%. Symptoms could be observed after the first cycle of chemotherapy, and the degree of renal impairment was higher with increased numbers of cycles (r=-0.946, $r^2=89.5%$). Factors that affected the decline of renal function were patient age (p=0.008, OR=3.433, 95%CI= 1.363-8.645) and hypertension (p=0.026, OR=2.931, 95%CI=1.120-7.670). Conclusions: Cisplatin nephrotoxicity occurred in more than one-third of patients after the fourth cycle of chemotherapy and worsened after each cycle despite preventive strategies such as hydration. The decline of renal function induced by cisplatin ${\geq}60mg/m^2$ was affected by age and hypertension.

Keywords

Cisplatin;Dharmais Hospital;nephrotoxicity;risk factor;hydration

References

  1. Aapro M, Launay-Vacher V (2012). Importance of monitoring renal function in patients with cancer. Cancer Treat Rev, 38, 235-40. https://doi.org/10.1016/j.ctrv.2011.05.001
  2. American Cancer Society (2008). Global cancer facts and figures 2008 2nd edition. [online]. [cited on March 28th, 2014] http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/ acspc-027766.pdf
  3. Ardizzoni A, Boni L, Tiseo M, et al (2007). Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst, 99, 847-57. https://doi.org/10.1093/jnci/djk196
  4. Arunkumar PA, Viswanatha GL, Radheshyam N, et al (2012). Science behind cisplatin-induced nephrotoxicity in humans: a clinical study. Asian Pac J Trop Biomed, 2, 640- 4. https://doi.org/10.1016/S2221-1691(12)60112-9
  5. BC Cancer Agency Cancer Drug Manual (2013). Cisplatin. [cited on June 3rd, 2013] http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Cisplatin.htm
  6. Bell JS, Blacker N, LeBlanc VT, et al (2013). Prescribing for older people with chronic renal impairment. Aust Fam Physician, 42, 24-8.
  7. Caglar K, Kinalp C, Arpaci F, et al (2002). Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of highdose chemotherapy followed by autologous stem-cell transplantation. Nephrol Dial Transplant, 17, 1931-5. https://doi.org/10.1093/ndt/17.11.1931
  8. Chu E, Sartorelli AC (2012). Cancer chemotherapy. In 'Basic and Clinical Pharmacology', Eds Katzung BG, Masters SB, Trevor AJ. 12nd ed. McGraw-Hill Companies Inc., USA pp 949-75.
  9. Corwin EJ (2008). Hypertension. Diabetes mellitus. In 'Handbook of Pathophysiology'. 3rd ed. Lippincott Williams and Wilkins, USA pp 430-34, 556-70.
  10. de Jongh FE, van Veen RN, Veltman SJ, et al (2003). Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer, 88, 1199-206. https://doi.org/10.1038/sj.bjc.6600884
  11. Erten C, Demir L, Somali I, et al (2013). Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients? Asian Pac J Cancer Prev, 14, 3711-7. https://doi.org/10.7314/APJCP.2013.14.6.3711
  12. Fine LG, Norman JT (2008). Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int, 74, 867-72. https://doi.org/10.1038/ki.2008.350
  13. Food and Drug Administration [FDA] (2010). Guidance for industry: Pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling. [cited on Sept 10th, 2013] http://www.fda.gov/ downloads/Drugs/.../Guidances/UCM204959.pdf
  14. Fujieda M, Matsunaga A, Hayashi A, et al (2009). Children's toxicology from bench to bed - drug-induced renal injury (2): nephrotoxicity induced by cisplatin and ifosfamide in children. J Toxicol Sci, 34, 251-7.
  15. Ghazali MV, Sastromihardjo S, Soedjarwo SR, et al (2011). A cross-sectional study. In 'Fundamentals of Clinical Research Methodology, Eds Sastroasmoro S and Ismael S. 4th ed. CV. Sagung Seto, Jakarta pp 130-45 (in Indonesian).
  16. Grover B, Buckley D, Buckley AR, et al (2004). Reduced expression of organic cation transporters rOCT1 and rOCT2 in experimental diabetes. J Pharmacol Exp Ther, 308, 949-56.
  17. Hill GS (2008). Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens, 17, 266-70. https://doi.org/10.1097/MNH.0b013e3282f88a1f
  18. Hotta K, Matsuo K, Ueoka H, et al (2004). Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol, 22, 3852-9. https://doi.org/10.1200/JCO.2004.02.109
  19. Jemal A, Bray F, Center MM, et al (2011). Global Cancer Statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  20. Khrunin A, Ivanova F, Moisseev A, et al (2012). Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. Pharmacogenomics, 13, 171-8. https://doi.org/10.2217/pgs.11.140
  21. Kroning R, Lichtenstein AK, Nagami GT (2000). Sulfurcontaining amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother Pharmacol, 45, 43-9. https://doi.org/10.1007/PL00006741
  22. Lacy CF, Armstrong LL, Goldman MP, et al (2011). Cisplatin. In 'Drug Information Handbook'. 20th ed. Lexi Comp., Ohio, 348-9.
  23. Lavole A, Danel S, Baudrin L, et al (2012). Routine administration of a single dose of cisplatin $\geq$75 mg/m2 after short hydration in an outpatient lung-cancer clinic. Bull Cancer, 99, 43-8.
  24. Leu L, Baribeault D (2010). A comparison of the rates of cisplatin (cDDP)-induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure. J Oncol Pharm Pract, 16, 167-71. https://doi.org/10.1177/1078155209346071
  25. Mathe C, Bohacs A, Duffek L, et al (2011). Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients. Eur Respir J, 37, 888-94. https://doi.org/10.1183/09031936.00055110
  26. Miller RP, Tadagavadi RK, Ramesh G, et al (2010). Mechanisms of cisplatin nephrotoxicity. Toxins, 2, 2490-518. https://doi.org/10.3390/toxins2112490
  27. Moon HH, Seo KW, Yoon KY, et al (2011). Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients. World J Gastroenterol, 17, 3510-7. https://doi.org/10.3748/wjg.v17.i30.3510
  28. Morgan KP, Buie LW, Savage SW (2012). The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy. Ann Pharmacother, 46, 276-81. https://doi.org/10.1345/aph.1Q333
  29. Muraki K, Koyama R, Honma Y, et al (2012). Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advenced non-small cell lung cancer. J Thorac Dis, 4, 562-8.
  30. Naughton CA (2008). Drug-induced nephrotoxicity. Am Fam Physician, 78, 743-50.
  31. Pabla N, Dong Z (2008). Cisplatin nephrotoxicity: mechanism and renoprotective strategies. Kidney Int, 73, 994-1007. https://doi.org/10.1038/sj.ki.5002786
  32. Perazella MA (2009). Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol, 4, 1275-83. https://doi.org/10.2215/CJN.02050309
  33. Reed E (2008). Pharmacology of cancer chemotherapy: cisplatin and its analogues. In 'Cancer Principles and Practice of Oncology', Eds De Vita VT Jr, Hellman S, Rosenberg SA. 8th ed. Lippincott Willians and Wilkins, Philadelphia.
  34. Ries F, Klastersky J (1986). Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis, 8, 368-79. https://doi.org/10.1016/S0272-6386(86)80112-3
  35. Santoso JT, Lucci JA 3rd, Coleman RL, et al (2003). Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol, 52, 13-8. https://doi.org/10.1007/s00280-003-0620-1
  36. Sinuraya ES (2012). The hospital based-cancer registry at Dharmais cancer hospital 2003- 2007. Jakarta: Indonesian J Cancer, 11-67 (in Indonesian).
  37. Stevens LA, Li S, Wang C, et al (2010). Prevalence of CKD and comorbid illness in elderly patients in the united states: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis, 55, 23-33. https://doi.org/10.1053/S0272-6386(10)00745-6
  38. Tan XL, Moyer AM, Fridley BL, et al (2011). Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res, 17, 5801-11. https://doi.org/10.1158/1078-0432.CCR-11-1133
  39. Tezcan S, Izzettin FV, Sancar M, et al (2013). Nephrotoxicity evaluation in outpatients treated with cisplatin-based chemotherapy using a short hydration method. Pharmacol Pharmacy, 4, 296-302. https://doi.org/10.4236/pp.2013.43043
  40. Thomas C, Thomas L (2009). Renal failure - measuring the glomerular filtration rate. Dtsch Arztebl Int, 106, 849-54.
  41. Tiseo M, Martelli O, Mancuso A, et al (2007). Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori, 93, 138-44.
  42. Wang J, Liu F, Huang DX, et al (2012). Post-operative treatment with cisplatin and vinorelbine in Chinese patients with nonsmall cell lung cancer: a clinical prospective analysis of 451 patients. Asian Pac J Cancer Prev, 13, 4505-10. https://doi.org/10.7314/APJCP.2012.13.9.4505
  43. Yamada K, Yoshida T, Zaizen Y, et al (2011). Clinical practice in management of hydration for lung cancer patients receiving cisplatin-based chemotherapy in Japan: a questionnaire survey. Jpn J Clin Oncol, 41, 1308-11. https://doi.org/10.1093/jjco/hyr145
  44. Yao X, Panichpisal K, Kurtzman N, et al (2007). Cisplatin nephrotoxicity: a review. Am J Med Sci, 334, 115-24. https://doi.org/10.1097/MAJ.0b013e31812dfe1e

Cited by

  1. Aging increases the susceptibility of cisplatin-induced nephrotoxicity vol.37, pp.6, 2015, https://doi.org/10.1007/s11357-015-9844-3
  2. Curcuma comosa ameliorates cisplatin-induced nephrotoxicity: COX-2 expression and ultrastructure changes vol.10, pp.34, 2016, https://doi.org/10.5897/JMPR2016.6151
  3. Nebivolol Ameliorates Cisplatin-Induced Nephrotoxicity in Rats vol.118, pp.6, 2016, https://doi.org/10.1111/bcpt.12538
  4. Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin vol.36, pp.7, 2018, https://doi.org/10.1200/JCO.2017.75.7161
  5. γ-secretase inhibitor DAPT mitigates cisplatin-induced acute kidney injury by suppressing Notch1 signaling pp.15821838, 2018, https://doi.org/10.1111/jcmm.13926
  6. Urinary biomarkers for early detection of platinum based drugs induced nephrotoxicity vol.19, pp.1, 2018, https://doi.org/10.1186/s12882-018-1022-2
  7. Evaluation of the effect of acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study pp.2210-7711, 2018, https://doi.org/10.1007/s11096-018-0677-x